stockrowBeam Therapeutics Inc.
BEAM Healthcare Biotechnology
Beam Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $139.7 million, up 120.0% from fiscal 2024.
- Revenue
- −96.8%
- EPS
- −16.7%
- Free cash flow
- −29.5%
Quarter to September 2026, against a year earlier
Follow BEAM
Alert me
Beam Therapeutics Inc. (BEAM) Revenue
Beam Therapeutics Inc.'s revenue for fiscal 2025 was $139.7M, up 120.0% from $63.5M in fiscal 2024. Over the twelve months to 30 September 2026 it was $146.6M. Over the past ten years it has ranged from $18.0K (fiscal 2019) to $377.7M (fiscal 2023); the current reading is higher than 86% of that period. Beam Therapeutics Inc. ranks 81st of 390 Biotechnology companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $139.7M | 120.01% |
| FY2024 | $63.5M | (83.18%) |
| FY2023 | $377.7M | 520.01% |
| FY2022 | $60.9M | 17.51% |
| FY2021 | $51.8M | 215,916.67% |
| FY2020 | $24.0K | 33.33% |
| FY2019 | $18.0K | — |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Sep 2026 | $307.0K | (37.35%) |
| Jun 2026 | $490.0K | (98.46%) |
| Mar 2026 | $31.7M | (72.19%) |
| Dec 2025 | $114.1M | 1,076.62% |
| 26 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| ZLAB Zai Lab Limited Unsponsored ADR compare | $441.7M |
| BEAM Beam Therapeutics Inc. | $146.6M |
| XNCR Xencor, Inc. compare | $105.0M |
| RCUS Arcus Biosciences, Inc. compare | $100.0M |
| IDYA IDEAYA Biosciences, Inc. compare | $36.5M |
| VRDN Viridian Therapeutics, Inc. compare | $26.3M |
| NAMS NewAmsterdam Pharma Company N.V. compare | $25.9M |
| TLX Telix Pharmaceuticals Limited compare | — |
| MBX MBX Biosciences, Inc. compare | — |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on BEAM
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement